Association for Molecular Pathology                       
Newsletter                                                                
   
February 2010, Volume 16, Number 1 

Inside this Issue

Front Page
President's Message
Special Features
• AMP 2009 Leadership Awardee
• AMP Award for Excellence in
  Molecular Diagnostics
• Executive Officer's Report
• Photo Contest Winners
• Annual Meeting Photo Album
• CHAMP
• JMD Report
• Web Editorial Board
Young Investigator Awards
• 2009 Young Investigator Awardees
Tech Corner
• 2009 Technologist Awardees
• 2009 Technologist Travel Awardees
Committee Reports
• Clinical Practice Committee
• Economic Affairs Committee
• Membership & Professional   
  Development Committee
• Nominating Committee
• Professional Relations
  Committee
• Program Committee
• Publications Committee
• Training & Education Committee
Subdivision Reports
• Genetics
• Hematopathology
• Infectious Diseases
• Solid Tumors
2010 AMP Officers and Appointees

Hematopathology Subdivision Report

Timothy C. Greiner, MD

By Timothy C. Greiner, MD
Chair, Hematopathology Subdivision

e-mail: tgreiner@unmc.edu

Greetings from the Hematopathology Subdivision! I thank Kojo Elenitoba-Johnson for his leadership in arranging the presentations for the 2009 AMP Annual Meeting.

During the 2009 AMP Meeting Bryan L. Betz did a practical review of the detection of mutations with prognostic implications in AML, including FLT3, NPM1, CEBPα and Ckit.  In the Hematopathology Plenary Session, Laura Pasqualucci and Vu Ngo discussed the new mutations, in genes such as CARD11 and A20, that were identified via pathway analysis of non-Hodgkin’s lymphoma. It is interesting that both diffuse large B-cell lymphoma and marginal zone lymphoma contained mutations in genes in the NFkB pathway. These discoveries may become of prognostic or targeted therapeutic importance in the future in lymphoma.  In the Hematopathology Workshop Josef T. Prchal presented the molecular background and Rebecca F. McClure discussed the practical aspects of JAK2 and MPL mutation testing in chronic myeloproliferative disorders. 

I thought that one of the most exciting events at the AMP Meeting was the Roche 454 Division announcement of the new GS Junior System, a smaller platform for next-generation sequencing. It will be interesting to see if the instrument will be more cost effective for exploration of the utility of next-generation sequencing in the clinical laboratory. At the Hematopathology Business Luncheon members indicated they were interested in a sample exchange project for JAK2 and MPL testing. Stay tuned for further information on this project that was suggested for consideration by Dan Sabath.

Planning is underway for the Plenary Session at the 2010 AMP Annual Meeting. There are new advances in the acute leukemias, with mutation analyses of neoplastic pathways and new findings from whole genome sequencing of the cancer genome.  We hope to have two speakers involved in whole genome analysis provide an update in this area.

Besides myself, the officers and representatives for 2009-2010 are as follows: 
Charles E. Hill, Chair-Elect
Joseph F. Pulliam (Clinical Practice Committee Representative)
Jane S. Gibson (Clinical Practice Committee Representative)
John W. Longshore (Nominating Committee Representative)
Domnita Crisan (Nominating Committee Representative)
Megan S. Lim (Training and Education Committee Representative)
Y. Lynn Wang (Training and Education Committee Representative)